132 related articles for article (PubMed ID: 27341410)
1. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer.
Teagle AR; Gilbert DC; Jones JR; Burkill GJ; McKinna F; Dizdarevic S
Nucl Med Commun; 2016 Oct; 37(10):1038-45. PubMed ID: 27341410
[TBL] [Abstract][Full Text] [Related]
2. Role of
Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
[TBL] [Abstract][Full Text] [Related]
3. Role of positron emission tomography-computed tomography in the management of anal cancer.
Mistrangelo M; Pelosi E; Bellò M; Ricardi U; Milanesi E; Cassoni P; Baccega M; Filippini C; Racca P; Lesca A; Munoz FH; Fora G; Skanjeti A; Cravero F; Morino M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):66-72. PubMed ID: 22592047
[TBL] [Abstract][Full Text] [Related]
4. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma.
Vercellino L; Montravers F; de Parades V; Huchet V; Kerrou K; Bauer P; Touboul E; Talbot JN
Int J Colorectal Dis; 2011 Feb; 26(2):201-10. PubMed ID: 21061012
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
[TBL] [Abstract][Full Text] [Related]
7. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
8. Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma.
Goldman KE; White EC; Rao AR; Kaptein JS; Lien WW
Pract Radiat Oncol; 2016; 6(5):e149-e154. PubMed ID: 26948134
[TBL] [Abstract][Full Text] [Related]
9. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
[TBL] [Abstract][Full Text] [Related]
10. PET/CT in anal cancer - is it worth doing?
Wells IT; Fox BM
Clin Radiol; 2012 Jun; 67(6):535-40. PubMed ID: 22208962
[TBL] [Abstract][Full Text] [Related]
11. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer.
Mistrangelo M; Pelosi E; Bellò M; Castellano I; Cassoni P; Ricardi U; Munoz F; Racca P; Contu V; Beltramo G; Morino M; Mussa A
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):73-8. PubMed ID: 19632066
[TBL] [Abstract][Full Text] [Related]
12. Can (18)F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer?
Ul-Hassan F; Simo R; Guerrero-Urbano T; Oakley R; Jeannon JP; Cook GJ
Clin Nucl Med; 2013 Apr; 38(4):263-5. PubMed ID: 23429398
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
14. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET/CT in the evaluation of anal carcinoma.
Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
[TBL] [Abstract][Full Text] [Related]
17. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
Winton Ed; Heriot AG; Ng M; Hicks RJ; Hogg A; Milner A; Leong T; Fay M; MacKay J; Drummond E; Ngan SY
Br J Cancer; 2009 Mar; 100(5):693-700. PubMed ID: 19259091
[TBL] [Abstract][Full Text] [Related]
18. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
19. Assessing the impact of FDG-PET in the management of anal cancer.
Nguyen BT; Joon DL; Khoo V; Quong G; Chao M; Wada M; Joon ML; See A; Feigen M; Rykers K; Kai C; Zupan E; Scott A
Radiother Oncol; 2008 Jun; 87(3):376-82. PubMed ID: 18453023
[TBL] [Abstract][Full Text] [Related]
20. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.
Taghipour M; Sheikhbahaei S; Trahan TJ; Subramaniam RM
Nucl Med Commun; 2016 Jun; 37(6):602-8. PubMed ID: 27110955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
